RegImmune (Mountain View, CA) early-stage biopharmaceutical company focused on the treatment of graft versus host disease, allergies, autoimmune diseases and other inflammatory diseases, closed a $8M Series B financing. Participants include NIF SMBC Ventures, CSK Venture Capital, Japan Asia Investment Co, and Yasuda Enterprise Development Co.